BackTable Urology
Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo
Dr. Andrea Apolo
But I don't understand why the combination didn't do as well as them or the monotherapy was the one that did the best, right? So that I wasn't sure if there was some antagonism or it was just the patients. These are really small numbers, right? I mean, the combination- I think it was like 50 patients versus 85 patients in the combination arm. So these are small numbers.
0
💬
0
Comments
Log in to comment.
There are no comments yet.